Previous close | 37.12 |
Open | 36.97 |
Bid | 37.71 x 0 |
Ask | 37.84 x 0 |
Day's range | 36.97 - 36.97 |
52-week range | 27.41 - 41.60 |
Volume | |
Avg. volume | 2 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Beyond analysts' top -and-bottom-line estimates for Halozyme Therapeutics (HALO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, investment in the fund returned 8.4% after all fees and expenses compared to 10.6% and 5.2% returns for the SP500TR and R2000 during the quarter, respectively. In addition, you […]
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.